Swartz S L, Williams G H, Hollenberg N K, Levine L, Dluhy R G, Moore T J
J Clin Invest. 1980 Jun;65(6):1257-64. doi: 10.1172/JCI109788.
Captopril is a potent hypotensive agent whose efficacy has hitherto been attributed to its ability to alter either angiotensin II formation or kinin degradation. Our purpose was to examine captopril's acute effect on prostaglandin production, because changes in neither the renin-angiotensin nor the kallikrein-kinin systems appear adequate to account for the fall in arterial pressure. The plasma levels of angiotensin II, kinins, and prostaglandins were determined in response to increasing doses (5, 12.5, and 25 mg) of captopril and these responses were compared with the change in arterial pressure observed in nine supine normal male subjects studied on both a high (200 meq) and low (10 meq) sodium intake.Captopril significantly (P < 0.01) increased the levels of the 13,14-dihydro-15-keto metabolite of prostaglandin E(2) (PGE(2)-M), a potent vasodilator, with similar responses being observed on both a high and a low sodium intake. No significant changes in the plasma levels of 6-keto-prostaglandin F (1)alpha, or thromboxane B(2), the stable products of prostacyclin and thromboxane A(2), respectively, occurred. The depressor response to captopril correlated with the change in PGE(2)-M (r = 0.52, t = 5.44, P < 0.0001). On the other hand, although significant (P < 0.02) decrements in angiotensin II and increments in plasma kinins accompanied the hypotensive response in sodium-restricted subjects, in sodium-loaded subjects where the renin-angiotensin system was suppressed, no change in angiotensin II, and only a modest change in kinins was noted, even though significant (P < 0.01) decrements in diastolic blood pressure occurred (-10+/-2 mm Hg).Thus, changes in depressor prostaglandin production can better account for the hypotensive response to captopril, thereby extending to yet another vasoactive system an influence by this class of drugs and providing a new approach to dissecting the abnormality in the control of vascular tone in patients with hypertension.
卡托普利是一种强效降压药,其疗效迄今被认为归因于它改变血管紧张素II生成或激肽降解的能力。我们的目的是研究卡托普利对前列腺素生成的急性影响,因为肾素-血管紧张素系统和激肽释放酶-激肽系统的变化似乎都不足以解释动脉血压的下降。在9名仰卧位正常男性受试者中,分别测定了高钠摄入(200毫当量)和低钠摄入(10毫当量)情况下,给予递增剂量(5、12.5和25毫克)卡托普利后血管紧张素II、激肽和前列腺素的血浆水平,并将这些反应与观察到的动脉血压变化进行比较。卡托普利显著(P<0.01)增加了前列腺素E2(PGE2-M)的13,14-二氢-15-酮代谢产物的水平,PGE2-M是一种强效血管舒张剂,在高钠和低钠摄入情况下均观察到类似反应。前列腺素I2的稳定产物6-酮-前列腺素F1α和血栓素A2的稳定产物血栓素B2的血浆水平均未发生显著变化。对卡托普利的降压反应与PGE2-M的变化相关(r = 0.52,t = 5.44,P<0.0001)。另一方面,虽然在钠摄入受限的受试者中,血管紧张素II显著降低(P<0.02)且血浆激肽增加伴随着降压反应,但在肾素-血管紧张素系统被抑制的钠负荷受试者中,尽管舒张压显著降低(P<0.01)(-10±2毫米汞柱),血管紧张素II没有变化,激肽只有适度变化。因此,降压性前列腺素生成的变化能更好地解释对卡托普利的降压反应,从而将这类药物的影响扩展到另一个血管活性系统,并为剖析高血压患者血管张力控制异常提供了一种新方法。